A 340B Vendor Draws Scrutiny from U.S. Senate

The 340B Drug Pricing Program has drifted from its original 1992 mission — a program designed to help safety-net providers stretch scarce federal resources has morphed into a complex financial ecosystem that often benefits large hospital systems, pharmacy benefit managers (PBMs), and for-profit intermediaries.

Policymakers are beginning to take notice of not just hospitals, but the companies they rely on to increase 340B revenue.

A U.S. Senate investigation is pulling back the curtain on one of the least understood players: the program’s prime vendor, Apexus. Senator Bill Cassidy (R-La.), a senior legislator and physician, recently launched a formal inquiry into Apexus, seeking to uncover how the vendor “generates its revenue and designs its commercial offerings.” This interest marks a critical transparency effort when it comes to entities managing our health care safety net.

The 80% Profit Margin

While the 340B program was intended to support vulnerable populations, this inquiry focuses on the financial incentives for the entities involved in its operation.

According to reports cited in the Senate inquiry, Apexus generated hundreds of millions of dollars in revenue through fees collected on almost every drug sold under the 340B program. The investigation notes that Apexus appears to have expanded its business beyond its core role as a vendor, working with covered entities to increase 340B utilization and creating additional business lines to increase its own profits.

Reports from The New York Times reinforce these concerns, with a recent article headlined “How a Company Makes Millions Off a Hospital Program Meant to Help the Poor.” Investigative journalists found that Apexus has worked behind the scenes to “supercharge” the program, prioritizing expansion and revenue. They note that the vendor was on track to garner $227 million in revenue in 2022, with profit margins exceeding 80 percent.

Oversight Questions

The Senate HELP Committee has noted that a “serious lack of transparency” prevents 340B discounts from translating into access or lower costs for patients in need, and the committee’s hearings on 340B have largely drawn bipartisan scrutiny of the program’s current operation.

The reality that entities managing and facilitating 340B are focused on commercial offerings and revenue generation-based program growth is another example of program dollars not being used as intended. Instead, for-profit institutions and middlemen are benefitting while patients continue to struggle with rising medical debt and limited access to care.